Live

Tariff updates: Trump escalates threats on China as markets remain jittery

Frankfurt - Delayed Quote EUR

Molecure S.A. (1B1.F)

1.8560

-0.2140

(-10.34%)

As of 9:56:01 AM GMT+2. Market Open.

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for 1B1.F

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.

Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.

Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs

Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs

Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway

Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway